Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

被引：0

作者：

Jesper van Breeschoten

Michel W. J. M. Wouters

Doranne L. Hilarius

John B. Haanen

Christian U. Blank

Maureen J. B. Aarts

Franchette W. P. J. van den Berkmortel

Jan-Willem B. de Groot

Geke A. P. Hospers

Ellen Kapiteijn

Djura Piersma

Roos S. van Rijn

Karijn P. M. Suijkerbuijk

Willeke A. M. Blokx

Bert-Jan J. ten Tije

Astrid A. M. van der Veldt

Art Vreugdenhil

Marye J. Boers-Sonderen

Alfonsus J. M. van den Eertwegh

机构：

[1] Dutch Institute for Clinical Auditing,Department of Medical Oncology

[2] Amsterdam UMC,Department of Surgical Oncology

[3] VU University Medical Center,Department of Pharmacy

[4] Cancer Center Amsterdam,Department of Medical Oncology and Immunology

[5] Netherlands Cancer Institute,Department of Molecular Oncology & Immunology

[6] Rode Kruis Ziekenhuis,Department of Medical Oncology

[7] Netherlands Cancer Institute,Department of Medical Oncology

[8] Netherlands Cancer Institute,Department of Medical Oncology

[9] Maastricht University Medical Centre,Department of Medical Oncology

[10] Zuyderland Medical Centre Sittard,Department of Internal Medicine

[11] Isala Oncology Center,Department of Internal Medicine

[12] Isala,Department of Medical Oncology

[13] University Medical Centre Groningen,Department of Pathology, Division of Laboratories

[14] Leiden University Medical Centre,Department of Internal Medicine

[15] Medisch Spectrum Twente,Departments of Medical Oncology and Radiology & Nuclear Medicine

[16] Medical Centre Leeuwarden,Department of Internal Medicine

[17] University Medical Centre Utrecht,Department of Medical Oncology

[18] Pharmacy and Biomedical Genetics,undefined

[19] University Medical Center Utrecht. Heidelberglaan 100,undefined

[20] Amphia Hospital,undefined

[21] Erasmus Medical Centre,undefined

[22] Maxima Medical Centre,undefined

[23] Radboud University Medical Centre,undefined

来源：

British Journal of Cancer | 2022年 / 126卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1362 / 1362

共 42 条

[21] Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients
Nakamura, Yasuhiro
Namikawa, Kenjiro
Kiniwa, Yukiko
Kato, Hiroshi
Yamasaki, Osamu
Yoshikawa, Shusuke
Maekawa, Takeo
Matsushita, Shigeto
Takenouchi, Tatsuya
Inozume, Takashi
Nakai, Yasuo
Fukushima, Satoshi
Saito, Shintaro
Otsuka, Atsushi
Fujimoto, Noriki
Isei, Taiki
Baba, Natsuki
Matsuya, Taisuke
Tanaka, Ryo
Kaneko, Takahide
Onishi, Masazumi
Kuwatsuka, Yutaka
Nagase, Kotaro
Onuma, Takehiro
Nomura, Motoo
Umeda, Yoshiyasu
Yamazaki, Naoya
EUROPEAN JOURNAL OF CANCER, 2022, 176 : 78 - 87
[22] The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAFV600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
Long, Georgina V.
Lebbe, Celeste
Atkinson, Victoria
Mandala, Mario
Nathan, Paul D.
Fernandez, A. N. A. Maria Arance
Richtig, Erika
Yamazaki, Naoya
Robert, Caroline
Schadendorf, Dirk
Tawbi, Hussein Abdul-Hassan
Ascierto, Paolo Antonio
Ribas, Antoni
Flaherty, Keith
Lee, Dung-Yang
Masood, Aisha
Gasal, Eduard
Dummer, Reinhard
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[23] Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Bai, Xue
Shaheen, Ahmed
Grieco, Charlotte
d'Arienzo, Paolo D.
Mina, Florentia
Czapla, Juliane A.
Lawless, Aleigha R.
Bongiovanni, Eleonora
Santaniello, Umberto
Zappi, Helena
Dulak, Dominika
Williamson, Andrew
Lee, Rebecca
Gupta, Avinash
Li, Caili
Si, Lu
Ubaldi, Martina
Yamazaki, Naoya
Ogata, Dai
Johnson, Rebecca
Park, Benjamin C.
Jung, Seungyeon
Madonna, Gabriele
Hochherz, Juliane
Umeda, Yoshiyasu
Nakamura, Yasuhiro
Gebhardt, Christoffer
Festino, Lucia
Capone, Mariaelena
Ascierto, Paolo Antonio
Johnson, Douglas B.
Lo, Serigne N.
Long, Georgina L.
Menzies, Alexander M.
Namikawa, Kenjiro
Mandala, Mario
Guo, Jun
Lorigan, Paul
Najjar, Yana G.
Haydon, Andrew
Quaglino, Pietro
Boland, Genevieve M.
Sullivan, Ryan J.
Furness, Andrew J. S.
Plummer, Ruth
Flaherty, Keith T.
ECLINICALMEDICINE, 2023, 65
[24] Comparing the clinical efficacies of anti-PD-1 antibody monotherapy and anti-PD-1 and anti-CTLA-4 combination therapy as first-line immunotherapy in Japanese advanced acral melanoma: A retrospective, multicenter study (JAMP-neo study).
Nakamura, Yasuhiro
Kiniwa, Yukiko
Kato, Hiroshi
Yamasaki, Osamu
Maekawa, Takeo
Matsushita, Shigeto
Takenouchi, Tatsuya
Inozume, Takashi
Nakai, Yasuo
Fukushima, Satoshi
Saito, Shintaro
Otsuka, Atsushi
Fujimoto, Noriki
Isei, Taiki
Baba, Natsuki
Matsuya, Taisuke
Tanaka, Ryo
Kaneko, Takahide
Onishi, Masazumi
Yoshikawa, Shusuke
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[25] Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
Nakamura, Y.
Namikawa, K.
Yoshikawa, S.
Kiniwa, Y.
Maekawa, T.
Yamasaki, O.
Isei, T.
Matsushita, S.
Nomura, M.
Nakai, Y.
Fukushima, S.
Saito, S.
Takenouchi, T.
Tanaka, R.
Kato, H.
Otsuka, A.
Matsuya, T.
Baba, N.
Nagase, K.
Inozume, T.
Fujimoto, N.
Kuwatsuka, Y.
Onishi, M.
Kaneko, T.
Onuma, T.
Umeda, Y.
Ogata, D.
Takahashi, A.
Otsuka, M.
Teramoto, Y.
Yamazaki, N.
ESMO OPEN, 2021, 6 (06)
[26] Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Brito, A. B. C.
Camandaroba, M. P. G.
de Lima, V. C. C.
ANNALS OF ONCOLOGY, 2020, 31 : S1401 - S1401
[27] Difference in oncological efficacy between subsequent anti-PD-L1 and anti-PD-1 inhibitors following first-line platinum-based chemotherapy for patients with advanced urothelial carcinoma
Kawashima, R.
Miyake, M.
Nishimura, N.
Sakamoto, K.
Miyamoto, T.
Iemura, Y.
Iida, K.
Tanaka, M.
Fujimoto, K.
ANNALS OF ONCOLOGY, 2024, 35 : S1516 - S1516
[28] Comparison of efficacy between anti-PD-1 antibody monotherapy and nivolumab plus ipilimumab therapy as first-line immunotherapy for advanced mucosal melanoma in Japanese patients: A single-center, retrospective cohort study
Horisaki, Ken
Yoshikawa, Shusuke
Omata, Wataru
Tsutsumida, Arata
Kiyohara, Yoshio
JOURNAL OF DERMATOLOGY, 2024, 51 (11): : 1425 - 1433
[29] Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy
Julian, Cristina
Machado, Robson J. M.
Girish, Sandhya
Chanu, Pascal
Heinzmann, Dominik
Harbron, Chris
Gershon, Anda
Pfeiffer, Shannon M.
Zou, Wei
Quarmby, Valerie
Zhang, Qing
Chen, Yachi
CANCER REPORTS, 2022, 5 (10)
[30] Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after de fi nitive surgery: a multicenter, retrospective cohort study (vol 65, 102290, 2023)
Bai, Xue
Shaheen, Ahmed
Grieco, Charlotte
Arienzo, Paolo D.
Mina, Florentia
Czapla, Juliane A.
Lawless, Aleigha R.
Bongiovanni, Eleonora
Santaniello, Umberto
Zappi, Helena
Dulak, Dominika
Williamson, Andrew
Lee, Rebecca
Gupta, Avinash
Li, Caili
Si, Lu
Ubaldi, Martina
Yamazaki, Naoya
Ogata, Dai
Johnson, Rebecca
Park, Benjamin C.
Jung, Seungyeon
Madonna, Gabriele
Hochherz, Juliane
Umeda, Yoshiyasu
Nakamura, Yasuhiro
Gebhardt, Christoffer
Festino, Lucia
Capone, Mariaelena
Ascierto, Paolo Antonio
Johnson, Douglas B.
Lo, Serigne N.
V. Long, Georgina
Menzies, Alexander M.
Namikawa, Kenjiro
Mandala, Mario
Guo, Jun
Lorigan, Paul
Najjar, Yana G.
Haydon, Andrew
Quaglino, Pietro
Boland, Genevieve M.
Sullivan, Ryan J.
Furness, Andrew J. S.
Plummer, Ruth
Flaherty, Keith T.
ECLINICALMEDICINE, 2024, 71

← 1 2 3 4 5 →